Below you’ll find all of our archived press releases, articles written by the Crohn's & Colitis Foundation, as well as research articles from external media sources. You can also search for a specific news item or topic by using direct keywords (for example, “the foundation research”) or by filtering the news by date or category.
Please note: If you are a member of the media interested in speaking with a foundation's spokesperson, contact us today.
For many patients the path to diagnosis and effective treatment is long and arduous, leading to delayed treatment and increased complications. Studies being presented at the Crohn’s & Colitis Congress — a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, on February 7-9 – reinforces the need for and highlights advances towards improved diagnosis of patients with IBD.
Increased patient-provider communication affects overall outcomes at every stage of the IBD patient journeyFebruary 7, 2019
It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Currently, there are no cures for these diseases. For many patients their disease impacts other areas of their health and well-being including aspects of their reproductive and mental health.
It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Currently, there are no cures for these diseases. Studies being presented at the Crohn’s & Colitis Congress — a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, on February 7-9 – highlights advancement in treatments for patients with IBD.
Crohn’s & Colitis Foundation Launches New Online Journal: Crohn’s & Colitis 360 to Inform and Catalyze Patient-Centered IBD CareJanuary 23, 2019
The Crohn’s & Colitis Foundation is launching a new open access journal to engage, inform, and catalyze dialogue on state-of-the-art, comprehensive care for more than 3 million Americans living with inflammatory bowel diseases (IBD). Crohn’s & Colitis 360 is a peer-reviewed, online-only forum for the publication of novel research and insights across key disciplines in IBD care. As an open access (OA) publication, Crohn’s & Colitis 360 is free and allows unrestricted online access to research outputs with no access fees. Manuscript submissions are now open at www.crohnscolitis360.org, with the first issue slated for May.
The Crohn’s & Colitis Congress®, the premier meeting for clinical and research professionals in the IBD space, has opened registration for the 2019 meeting. A partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA), the meeting will include four main sessions, as well as basic science sessions and pre-Congress workshops. The 2019 Crohn’s & Colitis Congress will take place February 7-9, 2019, at the Bellagio Hotel in Las Vegas.
Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Diseases (IBD) Receives FundingMay 17, 2018
Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.
Clinical trial recruitment is the biggest barrier to the development and approval of new treatments. In order to understand patient perceptions and improve recruitment, the Crohn’s & Colitis Foundation conducted in-person focus groups over a four-month period in 2016, the results of which are published in the paper "Crohn’s disease and ulcerative colitis patient perspectives on clinical trials and participation."
Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel DiseasesApril 17, 2018
The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.
The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis ServicesApril 11, 2018
Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.
exploring the relationship between accutane and ulcerative colitis
Crohn’s & Colitis Awareness Week kicks off on December 1, and in recognition of the observance, New Orleans Saints linebacker Michael Mauti will dedicate his cleats during Week 13 of the NFL season to help raise awareness of these inflammatory bowel diseases (IBD) and the critical work of the Crohn’s & Colitis Foundation to find cures for Crohn’s disease and ulcerative colitis. Mauti’s cleat design features the Foundation’s logo along with the Colitis Ninja, an icon of ulcerative colitis blogger Amber Elder, who is local to Mauti’s home state of Louisiana.